Immunotherapy of tumor by targeting angiogenesis |
| |
Authors: | Jianmei?Hou Ling?Tian Email author" target="_blank">Yuquan?WeiEmail author |
| |
Institution: | Key Laboratory of Biotherapy of Human Diseases of Ministry of Education,West China Hospital of Sichuan university,Chengdu 610041,China |
| |
Abstract: | Tumor growth and metastasis are angiogenesis-dependent. Anti-angiogenic therapy represents a new strategy for the development
of anti-cancer therapies. In recent years, there has been made great progress in anti-angiogenic therapy. As far as the passive
immunotherapy is concerned, a recombinant humanized antibody to vascular endothelial growth factor (VEGF)-Avastin has been
approved by FDA as the first angiogenesis inhibitor to treat colorectal cancer. For active specific immunotherapy, various
strategies for cancer vaccines, including whole endothelial cell vaccines, dendritic cell vaccines, DNA vaccines, and peptides
or protein vaccines, have been developed to break immune tolerance against important molecules associated with tumor angiogenesis
and induce angiogenesis-specific immune responses. This article reviews the angiogenesis-targeted immunotherapy of tumor from
the above two aspects. |
| |
Keywords: | angiogenesis tumor immunotherapy |
本文献已被 万方数据 SpringerLink 等数据库收录! |
|